Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel. Issue 4 (9th February 2021)

• Record Type: Journal Article
• Authors: Jiang, Wu; Li, Lin; Ke, Chuan-Feng; Wang, Wei; Xiao, Bin-Yi; Kong, Ling-Heng; Tang, Jing-Hua; Li, Yuan; Wu, Xiao-Dan; Hu, Ying; Guo, Wei-Hua; Wang, Si-Zhen; Wan, De-Sen; Xu, Rui-Hua; Pan, Zhi-Zhong; Ding, Pei-Rong
• Is Part Of: Journal of medical genetics. Volume 59:Issue 4(2022)
• Page Start: 370
• Page End: 376
• Publication Date: 2021-02-09
• Subjects: congenital -- hereditary -- and neonatal diseases and abnormalities -- gastroenterology -- genetic carrier screening -- genetic counseling; Medical genetics -- Periodicals; 616.042
• DOI: 10.1136/jmedgenet-2020-107230
• Languages: English
• ISSNs: 1468-6244

Abstract

Abstract : Purpose: Universal germline testing in patients with colorectal cancer (CRC) with a multigene panel can detect various hereditary cancer syndromes. This study was performed to understand how to choose a testing panel and whether the result would affect clinical management. Methods: We prospectively enrolled 486 eligible patients with CRC, including all patients with CRC diagnosed under age 70 years and patients with CRC diagnosed over 70 years with hereditary risk features between November 2017 and January 2018. All participants received germline testing for various hereditary cancer syndromes. Results: The prevalence of germline pathogenic variants (PVs) in cancer susceptibility genes was 7.8% (38/486), including 25 PVs in genes with high-risk CRC susceptibility (the minimal testing set) and 13 PVs in genes with moderate-risk CRC susceptibility or increased cancer risk other than CRC (the additional testing set). All the clinically relevant PVs were found in patients diagnosed under age 70 years. Among them, 11 patients would not have been diagnosed if testing reserved to present guidelines. Most (36/38) of the patients with PVs benefited from enhanced surveillance and tailored treatment. PVs in genes from the minimal testing set were found in all age groups, while patients carried PVs in genes from the additional testing set were older than 40 years. Conclusion: Universal germline testing for cancer susceptibility genes should be recommended among all patients with CRC diagnosed under age 70 years. A broad panel including genes from the additional testing set might be considered for patients with CRC older than 40 years to clarify inheritance risks. Trial registration number: NCT03365986 .